Direct evidence for a β₁-adrenergic receptor–directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy

Today, dilated cardiomyopathy (DCM) represents the main cause of severe heart failure and disability in younger adults and thus is a challenge for public health. About 30% of DCM cases are genetic in origin; however, the large majority of cases are sporadic, and a viral or immune pathogenesis is suspected. Following the established postulates for pathogenesis of autoimmune diseases, here we provide direct evidence that an autoimmune attack directed against the cardiac β₁-adrenergic receptor may play a causal role in DCM. First, we immunized inbred rats against the second extracellular β₁-receptor loop (β₁-EC_II; 100% sequence identity between human and rat) every month. All these rats developed first, receptor-stimulating anti–β₁-EC_II Ab’s and then, after 9 months, progressive severe left ventricular dilatation and dysfunction. Second, we transferred sera from anti–β₁-EC_II–positive and Ab-negative animals every month to healthy rats of the same strain. Strikingly, all anti–β₁-EC_II–transferred rats also developed a similar cardiomyopathic phenotype within a similar time frame, underlining the pathogenic potential of these receptor Ab’s. As a consequence, β₁-adrenergic receptor–targeted autoimmune DCM should now be categorized with other known receptor Ab-mediated autoimmune diseases, such as Graves disease or myasthenia gravis. Although carried out in an experimental animal model, our findings should further encourage the development of therapeutic strategies that combat harmful anti–β₁-EC_II in receptor Ab–positive DCM patients.

Heart muscle disease characterized by progressive dilatation and loss of cardiac function in the absence of known causes has been termed idiopathic dilated cardiomyopathy (DCM) (1, 2). Today, in Western countries DCM represents the main cause for severe heart failure and disability in younger adults (3). Several mutations in genes encoding for myocyte structural proteins (4, 5) and certain cardiotoxic substances (i.e., alcohol, anthracyclines) (6) account for about 30–40% of DCM cases; the etiology of the remaining 60–70%, however, is poorly understood. Current hypotheses regarding exogenous causes of DCM focus on chronic viral myocarditis (7) and/or on primary abnormalities in the immune system, including cytokine- or Ab-mediated tissue injury (8–10). In both cases the development of heart-specific autoantibodies has been reported (11–13). Recent clinical and experimental data suggest that among these Ab’s those directed against the cardiac β₁-adrenergic receptor (β₁-AR), in particular Ab’s that target the rather short but functionally important second extracellular receptor loop (β₁-EC_II), might play a key role in the pathogenesis of DCM (13, 14). Anti–β₁-EC_II Ab’s have been shown to activate the β₁-AR–signaling cascade in vitro (14–17), and in vivo they have been found to be associated with significantly poorer left ventricular function (18), a higher prevalence of serious ventricular arrhythmias (19), and a higher incidence of sudden cardiac death (20). It is still unclear, however, whether patients develop heart disease because they possess harmful anti–β₁-AR Ab’s or whether they develop anti–β₁-AR Ab’s as a result of cardiac tissue injury (13).

Following Witebsky’s postulates, indirect evidence for the autoimmune etiology of a disease requires (a) a corresponding self-antigen to be identified and (b) an analogous immune response to be induced in an experimental animal, which, finally, must also develop a similar disease (21, 22). Direct evidence, however, requires reproduction of the disease by transfer of homologous pathogenic Ab’s or pathogenic T cells, that is Ab’s or autoreactive T cells from one to another of the same species. Although it has been shown that β₁-EC_II represents a potent autoantigen (23, 24) and that intraperitoneal injection of blood lymphocytes from Ab-positive DCM patients into immunodeficient mice (to avoid the expected immune reaction against human non-self proteins) may lead to an early stage of heart dilatation (25), a cause-and-effect relation between anti–β₁-EC_II Ab’s and DCM has not yet been demonstrated. To accomplish the above-mentioned stringent criteria for autoimmune diseases, here we attempted to create experimental immune cardiomyopathy by immunizing inbred rats against β₁-EC_II (indirect evidence) and then to reproduce the disease in healthy rats of the same strain by transfer of the generated anti–β₁-EC_II Ab’s, thus mimicking autoantibodies (direct evidence).

Properties of rat anti–β₁-EC_II Ab’s and experimental strategy. In the first part of our study all 15 rats immunized with β₁-EC_II/GST fusion proteins produced high and uniform levels of anti–β₁-EC_II Ab’s of the IgG subclass (Figure 1A, inset), reaching a peak concentration of 0.68 ± 0.03 mg/ml 8 weeks after the first immunization, which decreased to 0.25 ± 0.03 mg/ml at the end of the study (as determined by immunopurified anti–rat IgG secondary Ab’s; Figure 1A). After preparation of the serum IgG fraction (caprylic acid precipitation), domain specificity of the generated Ab’s was checked by ELISA with selected peptides corresponding to the N terminus, C terminus, and EC_II domain of the β₁-AR or β₂-AR (Figure 2A). Using IFM we could demonstrate that all of these Ab’s recognized native β₁-AR expressed either in Sf9 insect cells or in HEK 293 eukaryotic cells (Figure 2, B and D), whereas nontransfected WT cells (devoid of β₁-AR and β₂-AR) were not stained at all. Importantly, these experiments revealed also that our rat anti–β₁-EC_II cross-reacts with neither the very closely related β₂-AR (expressed in Sf9 or HEK cells; Figure 2, B, and D) nor with another widely distributed cardiovascular receptor, that is, the angiotensin AT_1a receptor (Figure 2D). In addition, we could demonstrate that the rat anti–β₁-EC_II colocalized with N-immunolabeled β₁-AR in the membrane of HEK 293 cells (Figure 2D, double stain: rabbit anti–β₁-N/rat anti–β₁-EC_II). Only about 70% (n = 11/15) of the fluorescence-positive rat anti–β₁-EC_II, however, also stains SDS-denatured β₁-AR in Western blots of Sf9 cell lysates with the same intensity (compare Figure 2, B and C), confirming earlier data indicating a requirement for a specific native con-formation of the receptor being preferentially recognized by anti–β₁-EC_II Ab’s (14, 18).

Figure 1

Study protocol and anti–β₁-AR Ab’s. (A) The plotted curve indicates mean titers plus or minus SEM (error bars) of specific rat anti–β₁-EC_II (IgG subclass) during the immunization experiment. Time points of subcutaneous immunizations are indicated by arrows. The inset depicts the immunoreactivities of IgG prepared from all 15 β₁-EC_II–injected rats 3 months after the first immunization determined by ELISA. (B) Scheme depicting concentrations of rat anti–β₁-EC_II (serum pool and transferred amounts) during the transfer experiment. Time points of intravenous serum transfer are indicated by arrows. The inset shows representative mean titers plus or minus SEM after transfer of 0.7 ∝g anti–β₁-EC_II/g BW over a 4-week period and the derived half-life for rat anti–β₁-EC_II.

Figure 2

Immunological and functional properties of rat anti–β₁-EC_II. (A) ELISA immunoreactivities of different rat and rabbit Ab’s (see key) with peptide antigens corresponding to selected domains of the β₁- or β₂-AR (N terminus (N); C terminus (C); and EC_II-domain (EC_II)) (14). (B) IFM with unfixed (IgG diluted 1:200) or (C) Western blots (IgG diluted 1:2,000) with lysates of Sf9 insect cells expressing recombinant human β₁-AR, β₂-AR, or the WT vector. (D) IFM colocalization experiments with HEK 293 cells transiently expressing β₁-AR, β₂-AR, or flag-tagged AT_1a receptors (IgG diluted 1:200). Examples given are representative for IgG from β₁-EC_II–injected rats and a GST-injected rat (control); domain and β₁-AR/β₂-AR subtype-specific rabbit Ab’s (27) and a monoclonal mouse anti–AT_1a flag Ab (28) served to immunostain the corresponding receptors (β₁-AR, β₂-AR, and AT_1a receptor). (E) Increases in basal (–isoprenaline) or isoprenaline-stimulated (+10 ∝M/l isoprenaline) cAMP levels in Chinese hamster fibroblasts expressing human β₁-AR (CHW-β₁ cells) upon incubation with rat IgG (100 ∝g/ml). Columns represent amount of accumulated cAMP plus or minus SEM (error bars) obtained without (white, control) or in the presence of IgG from rats negative (light gray, GST/NaCl injected) or positive for functionally active anti–β₁-EC_II (black, β₁-EC_II injected). The stimulatory effects of anti–β₁-EC_II were blocked by 5 ∝M bisoprolol, a β₁-selective receptor antagonist (dark gray). **P < 0.001 (ANOVA and Scheff– F post hoc test).

As has been shown previously for human anti–β₁-EC_II (18), all of the generated rat anti–β₁-EC_II increased both the basal (1.25-fold ± 0.17-fold, P < 0.001) and the isoprenaline-stimulated cAMP-levels in CHW-β₁ cells (1.23-fold ± 0.09-fold, P < 0.001). Both effects were blocked by preincubation with 5 ∝M of the β₁-selective antagonist bisoprolol (Figure 2E), whereas maximum cAMP levels after direct stimulation of the G proteins with NaF did not change, excluding a postreceptor effect (not shown). Ab effects on PKA activity yielded substantially the same results (increase of basal and stimulated PKA activity by 1.23-fold ± 0.18-fold and 1.21-fold ± 0.06-fold, respectively; P < 0.01, not shown). Sera from both series of control animals (GST/NaCl) reacted with neither the β₁-EC_II peptide (ELISA) nor with β₁-AR expressed in Sf9 or in CHW cells (Western blot, IFM, and cAMP assay; Figure 2).The clearly defined and uniform immunological as well as functional properties of the generated rat anti–β₁-EC_II taken together with the use of an inbred rat strain (immunization experiment) made these Ab’s ideal candidates for a transfer experiment. For this purpose, we intravenously transferred the entire available Ab pool from the immunization study at monthly intervals to healthy rats of the same strain (12 injections of 0.7 ∝g/g BW anti–β₁-EC_II, Figure 1B). The respective peak concentrations of free anti–β₁-EC_II (4.7 ± 0.2 ∝g/ml) were about 50% lower than expected (i.e., approximately 11 ∝g/ml, considering a blood volume of 20 ml/300 g BW and 220 ∝g of transferred anti–β₁-EC_II), indicating significant tissue redistribution of the transferred Ab’s. Within 4 weeks (injection intervals) the concentration of transferred specific Ab’s further decreased to 0.6 ± 0.1 ∝g/ml, giving a calculated half-life for anti–β₁-EC_II of 9.3 days (Figure 1B, inset). Repetitive measurements of anti–β₁-EC_II levels at various time points after each serum transfer indicated that the Ab’s did not accumulate over time.

The acute effects of subcutaneous injection of the antigens and intravenous administration of the different sera (anti–β₁-EC_II, anti-GST, and NaCl control) were studied in naive rats of the same strain by invasively monitoring the responses in heart rate, blood pressure, and LV contractility (dp/dt_max [peak change in LV pressure per time (interval)]) over time. Whereas subcutaneous injection of the antigens did not influence any of the latter hemodynamic parameters (not shown), the transferred anti–β₁-EC_II Ab’s appeared to behave as mild β₁ agonists by inducing a transient slight but significant increase in LV contractility (dp/dt_max) accompanied by a transient significant increase in systolic blood pressure. These changes were observed only with anti–β₁-EC_II-containing sera, excluding a volume effect (Figure 3). Interestingly, the heart rate remained almost stable during the different injections, which is in perfect agreement with our data from long-term echocardiographic follow-up. There were no significant differences in heart rate between anti–β₁-EC_II-positive and Ab-negative animals over time, supporting the concept that, in the rat, cardiac β₁-AR might have a greater impact on parameters of LV contractility and relaxation than on chronotropy (35, 36).

Figure 3

In vivo short-term effects of rat anti–β₁-EC_II. (A) Single representative tracing and (B) panels depicting the time course of systolic LV pressure, heart rate, and dp/dt_max from naive Lewis/CrlBR rats after i.v. application of pooled sera from NaCl/GST-injected (control) or β₁-EC_II–injected rats (50 ∝l each). Arrows in A indicate time points of i.v. serum application. Error bars in B indicate mean plus or minus SEM of the indicated parameters normalized to the baseline (100%) at 0, 1, 2, 4, 6, and 8 minutes after serum application. *P < 0.05 (ANOVA and Bonferroni post hoc test). bpm; beats per minute.

Echocardiography and hemodynamic measurements. The echocardiographic system used in our study provided digitized images of high quality, which were routinely stored for computer-aided off-line analysis (Figure 4, A, C, and D). In addition, the system allowed for an analysis of M-mode and Doppler tracings directly on the screen (online) with an acceptable reproducibility at a high resolution (M-mode, 0.01 mm; Figure 4, B, E, and F). Evaluation of the accuracy of our echo-Doppler measurements yielded rather low intraobserver (1.7% M-mode and 2.1% Doppler, online and off-line measurements) and interobserver variabilities (3.2% M-mode and 4.5% Doppler, off-line measurements only), which are perhaps best explained by the recent progress in imaging technology.

Figure 4

Echocardiography of rat hearts. Digitally stored representative M-mode and Doppler images demonstrating (A) nonmarked and (B) online marked M-mode tracings from the same animal, off-line measured end-diastolic and end-systolic LV diameters (LVED/LVES) from (C) an anti–β₁-EC_II-positive and (D) a corresponding control animal (immunization experiment, month 15), and on-line determination of (E) LV outflow tract diameter (LVOT; M-mode tracings) and (F) aortic VTI in a same animal (Doppler tracings).

In the first part of our study we observed that LV dilatation and dysfunction in anti–β₁-EC_II-positive rats started about 9 months after immunization and then continuously progressed during the course of the experiment (Figure 5A; see also Figure 4, C and D). Interestingly, in the transfer experiment we obtained a similar echocardiographic pattern with an onset of cardiac dilatation and dysfunction also about 9 months after regular anti–β₁-EC_II-transfer (Figure 5B). At the end of each part of our study we checked the final echocardiographic findings by invasive measurements. We found that systolic LV pressure was constantly lower in Ab-positive than in corresponding control animals at a similar heart rate (Table 1). Most significantly, LV contractility (+dP/dt_max) and, in particular, LV relaxation (–dP/dt_max) were decreased to about the same extent in both β₁-EC_II–injected and anti–β₁-EC_II-transferred rats (P < 0.001 versus corresponding controls). Accordingly, LV end-diastolic pressure (LVEDP) tended to be higher in Ab-positive animals, but this failed to reach significance (Table 1). Thus, immunized rats and serum-transferred rats showed a clear functional deficit both by echocardiography and by catheterization.

Figure 5

Echocardiographic follow-up. (A) Immunization and (B) transfer experiment. The panels depict the time course of selected echocardiographic parameters. Upper panels: LVED and end-systolic diameters (LVES). Middle panels: fractional shortening (%), derived from (LVED-LVES/LVED ∞ 100), and heart rate (bpm). Lower panels: Cardiac index corresponding to CO/BW. CO (milliliters per minute) was assessed by echocardiography (see Methods). Error bars indicate mean plus or minus SEM.*P < 0.05; **P < 0.01; ***P < 0.001 (ANOVA and Bonferroni post hoc test).

Table 1

Hemodynamic and morphometric parameters of rat hearts

Cardiac anatomical measurements and tissue collagen I-III. The absolute (milligrams) and relative heart mass (milligrams per gram), as well as the size of the left ventricles, were significantly increased in both β₁-EC_II–injected and anti–β₁-EC_II-transferred rats compared with corresponding control animals (Table 1 and Figure 6B, left panels). As determined from H&E-stained midventricular 1-∝m sections (Figure 6A), in both parts of our study the increases in total LV area (LVA) were due to an increase in LV cavity area (LVCA) without a significant change in LV wall area (LVWA; Table 1 and Figure 6B, right panels). In fact, the thickness of the septum and the posterior wall was significantly decreased in Ab-positive versus control animals (Table 1 and Figure 6A). In both experiments echocardiography correlated well with the anatomic measurements, that is, predicted LV mass versus heart wet weight (r = 0.82 or 0.83) and echocardiographic versus anatomic left ventricular end-diastolic diameter (LVED) (r = 0.84 or 0.89; Figure 6B, insets). By light microscopic inspection of H&E-stained 1-∝m sections of the hearts, we did not detect any obvious signs of myocardial inflammation (i.e., cellular infiltrates, using a threshold of more than seven cells per square millimeter) in anti–β₁-EC_II-positive versus control rats (Figure 6C, left panels). In addition, the serum cytokine levels (i.e., TNF-α, IL-2, IL-6) between Ab-positive and control animals did not differ significantly (not shown). Further morphometric analysis of the heart sections, however, revealed significantly enlarged polymorphous nuclei and an increased nucleus-to-myocyte ratio in both β₁-EC_II–injected and anti–β₁-EC_II-transferred rats, whereas the size (i.e., diameter and perimeter) of the myocytes themselves did not differ significantly (Figure 6C, right panels). With respect to fibrosis, we did not observe an increase in total myocardial collagen I-III in hearts from β₁-EC_II-injected or anti–β₁-EC_II-transferred rats (Table 1), which is in perfect agreement with a recent report on rats with low-dose isoprenaline-induced cardiomyopathy (37).

Figure 6

Anatomic measurements and histology of rat hearts. (A) The panel shows representative H&E-stained 1-∝m cross-sections of hearts from an anti–β₁-EC_II-positive rat and a control animal (left row, ∞10 magnification). The middle and right rows indicate schematically how LV diameter, wall thickness, and different cardiac areas were determined by computer-aided image analysis. IVS, interventricular septum; LVD, LV-diameter; PW, posterior wall; RV, right ventricular; RVCA, right ventricular cavity area. (B) Immunization and transfer experiment. Left panels: Columns represent heart wet weight (HW) and the relative heart weight (HW/BW). The insets show correlations between wet weight and echocardiographically predicted HW for all animals (Ab-positive and Ab-negative rats) in each experiment. Right panels: Columns represent LV diameter (LVD), LVCA, and LVWA. The insets show correlations between the anatomic and the echocardiographic LV diameter for all animals in each experiment. Error bars indicate mean values plus or minus SEM. *P < 0.05; **P < 0.01; ***P < 0.001 (Student t test). (C) Immunization and transfer experiment. Left panels: H&E-stained 1-∝m sections of hearts from anti–β₁-EC_II-positive rats and corresponding control animals at ∞50 (upper rows) or ∞120 magnification (lower rows) with representative myocytes and corresponding nuclei. Right panels: Columns indicate the respective myocyte area (MA), nuclear area (NA), and the calculated nucleus-to-myocyte ratio (NA/MA). Error bars indicate mean values plus or minus SEM.

Cardiacβ₁-ARs and catecholamines. Using radioligand binding, we determined that total [¹²⁵I]-CYP binding sites were significantly decreased in hearts from β₁-EC_II–injected as well as anti–β₁-EC_II-transferred rats. Although we cannot exclude that age-dependent reductions in myocardial β-AR density (32) might have partially contributed to the absolute differences obtained between immunized and transferred rats (i.e., age 18 versus 15 months), this effect was clearly more pronounced in the immunization experiment resulting in about 30% downregulation of cardiac β-AR (Figure 7A) as compared with 18% downregulation in the transfer experiment (Figure 7B). Assuming a two-site binding model, the biphasic displacement curves in the presence of unlabeled β₁-AR selective antagonist CGP 20712A (Figure 7A, inset) revealed that this downregulation was primarily a function of diminished cardiac β₁-AR density in both parts of our study (thus age independent), whereas the absolute number of cardiac β₂-AR did not change substantially (Figure 7, A and B). When comparing the epinephrine and norepinephrine levels from urine samples collected over 24 hours at the beginning (not shown) and the end of each experiment, however, we found no significant differences between anti–β₁-EC_II-positive and corresponding control animals (Figure 7, C and D).

Figure 7

β₁-AR/β₂-AR subtypes and urine catecholamines. (A) Immunization and (B) transfer experiment. Columns represent total β-AR density and the amount of β₁-AR and β₂-AR subtypes (femtomoles per milligram of protein) in cardiac membranes of β₁-EC_II–injected (n = 15, aged 18 months) or anti–β₁-EC_II-transferred rats (n = 10, aged 15 months), and corresponding control animals at the end of each experiment (n = 20 or n = 10, respectively). Error bars indicate mean values plus or minus SEM. **P < 0.01; ***P < 0.001. The inset in A depicts a representative radioligand displacement curve using the β₁-selective antagonist CGP 20712A (immunization experiment). (C) Immunization and (D) transfer experiment. Columns correspond to urine catecholamine concentrations determined at study end. Error bars indicate mean values plus or minus SEM.

Proof of a pathogenetic principle. The two major hypotheses on the exogenous causes of idiopathic DCM are either persistent viral infection (7, 38) or autoimmune-mediated damage to myocytes (8, 10–13). Actually, the hypotheses are not mutually exclusive because a large number of autoimmune reactions to myocardial proteins appear to be virus triggered (11, 38). An important prerequisite for potentially pathogenic autoantibodies is their ability to (a) recognize their corresponding antigens in a native conformation and (b) exert pathophysiologically relevant functional effects (39). Therefore, autoantibodies that bind to and activate cardiac β₁-ARs have been claimed as promising candidates involved in the pathogenesis of DCM (13, 14, 16, 18, 25). A cause-and-effect relation between anti–β₁-AR autoantibodies and the disease remained to be demonstrated (13), however. Following the stringent established postulates for autoimmune diseases (22), we provide here direct evidence that an autoimmune attack to the β₁-EC_II may play a causal role in DCM: we immunized inbred rats against β₁-EC_II (100% sequence-identity between human and rat) in order to induce both the potentially harmful anti–β₁-EC_II Ab’s and the disease. All these rats developed receptor-stimulating anti–β₁-EC_II, and from the ninth immunization month onward, progressive LV dilatation and dysfunction (indirect evidence). In the following step, we mimicked autoantibodies by transferring anti–β₁-EC_II from immunized rats to healthy rats of the same strain. The fact that all healthy rats within a similar time frame also developed a cardiomyopathic phenotype finally delivered the direct proof of the (pathogenetic) principle.

Cardiomyopathic phenotypes induced by immunization againstβ₁-EC_II. For more than a decade it has been well established that β₁-EC_II represents a potent autoantigen containing the T and B cell epitopes necessary for induction of an immune response (23, 24). In addition, we and others have previously shown that both synthetic peptides corresponding to β₁-EC_II and/or fusion proteins containing β₁-EC_II induce functionally active anti–β₁-EC_II Ab’s in rabbits (14, 40, 41). Two groups also reported on the morphological changes observed in the hearts of anti–β₁-EC_II-positive rabbits (post mortem examinations); the results, however, differed to some extent, demonstrating either biventricular dilatation without a change in myocardial fibrosis (40) or LV hypertrophy with an increase in fibrosis (41). None of the earlier immunization studies have addressed the in vivo functional consequences of anti–β₁-EC_II Ab’s, however. By echocardiographic follow-up of β₁-EC_II–injected rats we demonstrate here a time course of LV dilatation with an onset of anti–β₁-EC_II-mediated immune cardiomyopathy about 9 months after the generation of activating anti–β₁-EC_II. This LV dilatation and dysfunction slowly but steadily progressed during the study, resulting in physical signs of heart failure in all anti–β₁-EC_II-positive animals (reduced activity, intraperitoneal edema, hepatic enlargement). Because of the planned hemodynamic measurements in vivo and the planned serum transfer, however, we stopped the immunization experiment before the animals developed end-stage heart failure with an increase in mortality. Interestingly, also in the transfer experiment (in which the duration was limited by the pool of anti–β₁-EC_II-containing sera), cardiac dilatation and dysfunction were apparent about 9 months after regular Ab transfer, suggesting the same slow-acting pathogenetic mechanism in both parts of our study. In view of the functional effects of our anti–β₁-EC_II in vitro and their hemodynamic short-term effects in vivo (which are in perfect agreement with the electrophysiological and hemodynamic effects of human anti–β₁-EC_II observed in isolated rat cardiomyocytes) (17), the most likely explanation is that, in our model, the Ab’s acted as mild β₁ agonists, which, over time, might have initiated and/or worsened the vicious circle of sympathetic overdrive and progressive heart failure. The fact that we were able to transfer the disease by relatively low amounts of anti–β₁-EC_II (compared with immunized animals) indicates (a) that the measured serum levels after transfer of anti–β₁-EC_II were not representative of the true amount of functionally relevant Ab’s acting in these animals (approximately 50% tissue redistribution) and (b) that the biological efficiency of the Ab’s was rather high, which means that in our model the absolute amount of circulating anti–β₁-EC_II appeared to be less important than the pathogenic potential of each receptor Ab bound. Taken together, these data demonstrate that development of anti–β₁-AR-induced immune cardiomyopathy is a slow but continuously progressing process, which is perhaps best mimicked by low-dose isoprenaline-induced heart failure models (37). This notion is further supported by the fact that total myocardial collagen was not increased in either low-dose agonist–induced or in anti–β₁-AR-induced cardiomyopathy. Further microstructural analysis of the hearts from Ab-positive rats revealed enlarged and polymorphous nuclei without a significant increase in myocyte size, however. This feature is frequently found in failing cardiomyopathic hearts (42, 43) and thought to reflect changes in gene expression (i.e., induction of specific members of the embryonic gene program, including the atrial natriuretic factor gene) (44) as a compensatory response to both sympathetic overdrive and hemodynamic overload, with the degree of dilatation exceeding the capacity to hypertrophy (44, 45).

Functional properties of anti–β₁-EC_II Ab’s. We show here that anti–β₁-EC_II generated in rats uniformly increases both basal and agonist-stimulated cAMP levels and PKA activity in CHW-β₁ cells to about the same extent as has been demonstrated for human anti–β₁-EC_II (15, 18). The cAMP effects were blocked by the β₁-specific antagonist bisoprolol, suggesting that our stimulatory rat anti–β₁-EC_II acted, indeed, via the β₁-AR. By contrast, anti–β₁-EC_II raised in rabbits exhibited inconsistent functional properties. Some rabbit anti–β₁-EC_II increased basal and partially inhibited isoprenaline-stimulated cAMP levels (partial agonist-like effect) (41), whereas others blocked both basal and agonist-stimulated receptor signaling (14). Accordingly, in one of the immunization studies with rabbits, cardiac β₁-ARs were upregulated in the presence of receptor Ab’s (40), whereas in the other they were downregulated (41). As suggested in a recent report focusing on the role of the MHC in the elaboration of autoantibodies, some of these differences might derive from the specific epitope-dependent functional properties of the generated anti–β₁-EC_II (epitope defined as sequence of individually recognized AAs) (39). Allosterically blocking (inhibitory) anti–β₁-EC_II would be expected to upregulate cardiac β₁-AR, whereas receptor-stimulating anti–β₁-EC_II should induce β₁-AR downregulation (14, 41). The transfer experiment further highlights the importance of the functional properties of an Ab and/or autoantibody for its pathogenicity (46). Independent of an age-associated reduction in total β-AR density (32), we show here that our stimulating rat anti–β₁-EC_II almost selectively downregulates cardiac β₁-AR, even at a 25-fold (calculated) or 50-fold (measured) dilution compared with anti–β₁-EC_II levels in immunized rats, suggesting a high biological activity and/or efficiency of these Ab’s.

Anti–β₁-EC_II-targeted autoimmune cardiomyopathy: study limitations and future perspectives. In summary, anti–β₁-AR-targeted autoimmune cardiomyopathy in the rat is characterized by the following: (a) progressive LV dilatation and dysfunction; (b) a relative decrease in LV wall thickness; and (c) downregulation of β₁-AR, a feature that is also seen in human DCM (47). Our data suggest that both the induced and the transferred cardiomyopathic phenotypes must be attributed mainly to the mild but sustained receptor activation by stimulating anti–β₁-EC_II. This notion is further supported by the fact that serum cytokine levels were not significantly different between Ab-positive and corresponding control animals and that the selective downregulation of cardiac β₁-AR in Ab-positive animals occurred in the absence of elevated catecholamines. The observation that both the induced and the transferred cardiomyopathic phenotypes developed within a similar time frame, however, remains open to speculation. Assuming a mild β₁ agonistic behavior of the generated Ab’s in vivo (see Figure 3), it seems conceivable that in the first part of our experiment (immunization with β₁-EC_II) maximal circulating concentrations of anti–β₁-EC_II did not develop until 2–3 months after immunization (see Figure 1A). By contrast, in the second part of the study (transfer of anti–β₁-EC_II to naive animals) a lower concentration of Ab’s was active from the very beginning of the experiment. Thus, it is conceivable that differences in lag time of Ab generation and concentration between the two series result in similar time courses of disease development. For this point our study does not allow final conclusions, because echocardiograms were obtained at 3-month intervals only, making it difficult to retrospectively determine the exact time point of disease onset with one or the other protocol.

The aim of our study was to analyze the potential pathogenic significance of autoantibodies targeting cardiac β₁-AR in DCM by testing the established postulates for autoimmune diseases in an animal model. Therefore, in the present work we focused on the immunological and functional characterization of the generated receptor Ab’s and on the morphological (echocardiography and anatomy) and functional characterization of the hearts from our rats, including a precise analysis of their cardiac membrane β₁-AR (with experiments done at least in triplicate). After the binding experiments, only a faint amount of fresh-frozen cardiac tissue remained from some but not all of our rats, precluding further valid gene expression analyses in the frame of this study. By accomplishing the established postulates for pathogenesis of an autoimmune disease, however, the presented data here indicate that β₁-AR–targeted autoimmune DCM should now be categorized with other known receptor Ab–mediated diseases such as Graves disease, myasthenia gravis, or type B insulin-resistant diabetes (48). Although carried out in an experimental animal model, our study might, therefore, also serve as a basis for more specific therapeutic approaches in Ab-positive human DCM patients. These would include pharmacological neutralization of functionally active anti–β₁-AR Ab’s by β₁-AR blockade and/or their elimination by nonselective (49, 50) or, perhaps more desirable, anti–β₁-AR-selective immunoadsorption (51). In addition, the anti–β₁-AR-producing B cells themselves might represent an interesting target for future therapies.

Our work was supported by the Deutsche Forschungsgemeinschaft (Grant Ja 706/2-1).

See the related Commentary beginning on page 1379.

Nonstandard abbreviations used: β₁-adrenergic receptor (β₁-AR); β₁-AR second extracellular receptor loop (β₁-EC_II); body weight (BW); cAMP-dependent protein kinase (PKA); cardiac output (CO); dilated cardiomyopathy (DCM); glutathione-S-transferase (GST); human embryonal kidney (HEK); immunofluorescence microscopy (IFM); ¹²⁵I-labeled cyanopindolol ([¹²⁵I]-CYP); isobutylmethylxanthine (IBMX); left ventricular (LV); LV end-diastolic diameter (LVED); LV end-diastolic pressure (LVEDP); LV area (LVA); LV cavity area (LVCA); LV wall area (LVWA); peak change in LV pressure per time (interval) (dp/dt_max); velocity–time integral (VTI).

Conflict of interest: The authors have declared that no conflict of interest exists.

1. Richardson, P, et al. Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Circulation. 1996. 93:841-842.
   View this article via: PubMed Google Scholar
2. Felker, GM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N. Engl. J. Med. 2000. 342:1077-1084.
   View this article via: PubMed CrossRef Google Scholar
3. Centers for Disease ControlPrevention. Changes in mortality from heart failure, United States. J. Am. Med. Assoc. 1998. 280:874-875.
   View this article via: CrossRef Google Scholar
4. Graham, RM, Owens, WA. Pathogenesis of inherited forms of dilated cardiomyopathy. N. Engl. J. Med. 1999. 341:1759-1762.
   View this article via: PubMed CrossRef Google Scholar
5. Seidman, JG, Seidman, C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 2001. 104:557-567.
   View this article via: PubMed CrossRef Google Scholar
6. Fabrizio, L, Regan, TJ. Alcoholic cardiomyopathy. Cardiovasc. Drugs Ther. 1994. 8:89-94.
   View this article via: PubMed CrossRef Google Scholar
7. Kuhl, U, Noutsias, M, Seeberg, B, Schultheiss, HP. Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy. Heart. 1996. 75:295-300.
   View this article via: PubMed CrossRef Google Scholar
8. Luppi, P, et al. Idiopathic dilated cardiomyopathy. A superantigen-driven autoimmune disease. Circulation. 1998. 98:777-785.
   View this article via: PubMed Google Scholar
9. Limas, CJ, et al. Prognostic significance of soluble interleukin-2 receptor levels in patients with dilated cardiomyopathy. Eur. J. Clin. Invest. 2003. 33:443-448.
   View this article via: PubMed CrossRef Google Scholar
10. Eriksson, U, et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat. Med. 2003. 9:1484-1490.
    View this article via: PubMed CrossRef Google Scholar
11. Caforio, AL, et al. Organ-specific cardiac autoantibodies in dilated cardiomyopathy — an update. Eur. Heart J. 1995. 16(Suppl. O):68-70.
    View this article via: PubMed Google Scholar
12. Matsui, S, Fu, M. Characteristic distribution of circulating autoantibodies against G-protein coupled receptors in patients with idiopathic dilated and hypertrophic cardiomyopathy. Int. J. Cardiol. 1996. 54:143-147.
    View this article via: PubMed CrossRef Google Scholar
13. Limas, CJ. Cardiac autoantibodies in dilated cardiomyopathy. Circulation. 1997. 95:1979-1980.
    View this article via: PubMed Google Scholar
14. Jahns, R, et al. Modulation of β1-adrenoceptor activity by domain-specific antibodies and heart failure-associated autoantibodies. J. Am. Coll. Cardiol. 2000. 36:1280-1287.
    View this article via: PubMed CrossRef Google Scholar
15. Limas, CJ, Goldenberg, IF, Limas, C. Influence of anti-β-receptor antibodies on cardiac adenylate cyclase in patients with idiopathic dilated cardiomyopathy. Am. Heart J. 1990. 119:1322-1328.
    View this article via: PubMed CrossRef Google Scholar
16. Magnusson, Y, Wallukat, G, Waagstein, F, Hjalmarson, Å, Hoebeke, J. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the β1-adrenoceptor with positive chronotropic effect. Circulation. 1994. 89:2760-2767.
    View this article via: PubMed Google Scholar
17. Christ, T, et al. Autoantibodies against the β1-adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J. Mol. Cell. Cardiol. 2001. 33:1515-1525.
    View this article via: PubMed CrossRef Google Scholar
18. Jahns, R, et al. Autoantibodies activating human β1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation. 1999. 99:649-654.
    View this article via: PubMed Google Scholar
19. Chiale, PA, et al. Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus node dysfunction. Circulation. 2001. 103:1765-1771.
    View this article via: PubMed Google Scholar
20. Iwata, M, et al. Autoantibodies against the second extracellular loop of β1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 2001. 37:418-424.
    View this article via: PubMed CrossRef Google Scholar
21. Witebsky, E, Rose, NR, Terplan, K, Paine, JR, Egan, RW. Chronic thyroiditis and autoimmunization. J. Am. Med. Assoc. 1957. 164:1439-1447.
    View this article via: PubMed Google Scholar
22. Rose, NR, Bona, C. Defining criteria for autoimmune diseases (Witebsky’s postulates revisited). Immunol. Today. 1993. 14:426-430.
    View this article via: PubMed CrossRef Google Scholar
23. Magnusson, Y, et al. Antigenic analysis of the second extracellular loop of the human β-adrenergic receptors. Clin. Exp. Immunol. 1989. 78:42-48.
    View this article via: PubMed Google Scholar
24. Mobini, R, et al. Probing the immunological properties of the extracellular domains of the human β1-adrenoceptor. J. Autoimmun. 1999. 13:179-186.
    View this article via: PubMed CrossRef Google Scholar
25. Omerovic, E, et al. Induction of cardiomyopathy in severe combined immunodeficiency mice by transfer of lymphocytes from patients with idiopathic dilated caediomyopathy. Autoimmunity. 2000. 32:271-280.
    View this article via: PubMed Google Scholar
26. Frielle, T, et al. Cloning of the cDNA for the human β1-adrenergic receptor. Proc. Natl. Acad. Sci. U. S. A. 1987. 84:7920-7924.
    View this article via: PubMed CrossRef Google Scholar
27. Jahns, R, et al. Probing human β1- and β2-adrenoceptors with domain-specific fusion protein antibodies. Eur. J. Pharmacol. 1996. 316:111-121.
    View this article via: PubMed CrossRef Google Scholar
28. Hein, L, Meinel, L, Pratt, RE, Dzau, VJ, Kobilka, BK. Intracellular trafficking of angiotensin II and its AT₁ and AT₂ receptors: evidence for selective sorting of receptor and ligand. Mol. Endocrinol. 1997. 11:1266-1277.
    View this article via: PubMed CrossRef Google Scholar
29. Roskoski, R. Assays of protein kinase. Meth. Enzymol. 1983. 99:3-7.
    View this article via: PubMed CrossRef Google Scholar
30. Litwin, SE, Katz, SE, Morgan, JP, Douglas, PS. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation. 1994. 89:345-354.
    View this article via: PubMed Google Scholar
31. Lopez-De Leon, A, Roijkind, M. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J. Histochem. Cytochem. 1985. 33:737-743.
    View this article via: PubMed Google Scholar
32. Xiao, RP, et al. Age-associated reductions in cardiac β1- and β2-adrenergic responses without changes in inhibitory G proteins or receptor kinases. J. Clin. Invest. 1998. 101:1273-1282.
    View this article via: JCI PubMed CrossRef Google Scholar
33. Hein, L, Altman, JD, Kobilka, BK. Two functionally distinct α₂-adrenergic receptors regulate sympathetic neurotransmission. Nature. 1999. 402:181-184.
    View this article via: PubMed CrossRef Google Scholar
34. Bland, JM, Altmann, DG. Statistical methods for assessing agreement between two methods of clinical assessment. Lancet. 1986. 1:307-310.
    View this article via: PubMed Google Scholar
35. Xiao, RP, Lakatta, EG. β1-adrenoceptor stimulation and β2-adrenoceptor stimulation differ in their effects on contraction, cytosolic Ca²⁺, and Ca²⁺ current in single rat ventricular cells. Circ. Res. 1993. 73:286-300.
    View this article via: PubMed Google Scholar
36. Xiao, RP, Cheng, H, Zhou, YY, Kuschel, M, Lakatta, EG. Recent advances in cardiac β2-adrenergic signal transduction. Circ. Res. 1999. 85:1092-1100.
    View this article via: PubMed Google Scholar
37. Woodiwiss, AJ, et al. Reduction in myocardial collagen cross-linking parallels left ventricular dilatation in rat models of systolic chamber dysfunction. Circulation. 2001. 103:155-160.
    View this article via: PubMed Google Scholar
38. Rose, NR. Infection, mimics, and autoimmune disease. J. Clin. Invest. 2001. 107:943-944.
    View this article via: JCI PubMed CrossRef Google Scholar
39. Limas, CJ. Autoimmunity in dilated cardiomyopathy and the major histocompatibility complex. Int. J. Cardiol. 1996. 54:113-116.
    View this article via: PubMed CrossRef Google Scholar
40. Matsui, S, et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J. Mol. Cell Cardiol. 1997. 29:641-655.
    View this article via: PubMed CrossRef Google Scholar
41. Iwata, M, et al. Autoimmunity against the second extracellular loop of β1-adrenergic receptors induces β-adrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ. Res. 2001. 88:578-586.
    View this article via: PubMed Google Scholar
42. Scholz, D, Diener, W, Schaper, J. Altered nucleus/cytoplasm relationship and degenerative structural changes in human dilated cardiomyopathy. Cardioscience. 1994. 5:127-138.
    View this article via: PubMed Google Scholar
43. Yan, SM, Finato, N, Di Loreto, C, Beltrami, CA. Nuclear size of myocardial cells in end-stage cardiomyopathies. Anal. Quant. Cytol. Histol. 1999. 21:174-180.
    View this article via: PubMed Google Scholar
44. Chien, KR, Knowlton, KU, Zhu, H, Cien, S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiological response. FASEB J. 1991. 5:3037-3046.
    View this article via: PubMed Google Scholar
45. Davies, CH, Harding, SE, Poole-Wilson, PA. Cellular mechanisms of contractile dysfunction in human heart failure. Eur. Heart J. 1996. 17:189-198.
    View this article via: PubMed Google Scholar
46. Kuan, AP, Zuckier, L, Liao, L, Factor, SM, Diamond, B. Immunoglobulin isotype determines pathogenicity in antibody-mediated myocarditis in naive mice. Circ. Res. 2000. 86:281-285.
    View this article via: PubMed Google Scholar
47. Staudt, A, et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation. 2001. 103:2681-2686.
    View this article via: PubMed Google Scholar
48. Fraser, CM, Venter, JC. Anti-receptor antibodies in human disease. J. Allergy Clin. Immunol. 1984. 74:661-673.
    View this article via: PubMed CrossRef Google Scholar
49. Müller, J, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation. 2000. 101:385-391.
    View this article via: PubMed Google Scholar
50. Felix, SB, et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J. Am. Coll. Cardiol. 2000. 35:1590-1598.
    View this article via: PubMed CrossRef Google Scholar
51. Wallukat, G, Müller, J, Hetzer, R. Specific removal of β1-adrenergic antibodies directed against cardiac proteins from patients with idiopathic dilated cardiomyopathy [letter]. N. Engl. J. Med. 2002. 347:1806.
    View this article via: PubMed CrossRef Google Scholar